Predictive value of combining the level of lipoprotein-associated phospholipase A2 and antithrombin III for acute coronary syndrome risk

Lu,Jinyang; Niu,Dandan; Zheng,Di; Zhang,Quan; Li,Wenhua

doi:10.3892/br.2018.1162

Predictive value of combining the level of lipoprotein-associated phospholipase A2 and antithrombin III for acute coronary syndrome risk

Authors:
- Jinyang Lu
- Dandan Niu
- Di Zheng
- Quan Zhang
- Wenhua Li
View Affiliations

Affiliations: Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China, Department of Cardiology, The Third People's Hospital of Xuzhou, Xuzhou, Jiangsu 221003, P.R. China
Published online on: October 19, 2018 https://doi.org/10.3892/br.2018.1162
Pages: 517-522

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to observe the role of lipoprotein-associated phospholipase A2 (Lp-PLA2) and antithrombin III (AT-III) in patients with acute coronary syndrome (ACS), and the combination of Global Registry of Acute Coronary Events (GRACE) score to determine the value of coronary heart disease risk stratification. A total of 309 patients admitted to the Affiliated Hospital of Xuzhou Medical University were enrolled. The patients were divided into two groups: The ACS (183 cases) and control (126 cases) groups. Blood levels of Lp-PLA2 and AT-III were measured. Based on GRACE score, the patients with ACS were divided into three subgroups: Low risk (GRACE score ≤108), middle risk (GRACE score 109-140) and high risk (GRACE score >140). The levels of Lp-PLA2 and AT-III were compared among different groups, and based on Gensini score, patients with ACS were divided into four groups by quartiles. Lp-PLA2 levels in the ACS group were significantly increased compared with the control group (P<0.05), but the AT-III levels were decreased compared with the control group (P<0.05). In the ACS group, Lp-PLA2 levels increased sequentially from the low risk to high risk subgroups (all P<0.05); compared with the low risk and middle risk subgroups, the AT-III activity levels were decreased in the high risk subgroup, and the Gensini scores were increased (all P<0.05). In the ACS group, with the increase of Gensini scores, the levels of Lp-PLA2 and AT-III exhibited increasing and decreasing trends, respectively (P<0.05). The logistic regression model demonstrated that Lp-PLA2 [odds ratio (OR) =1.077; P<0.001]; and GRACE score (OR=1.026; P=0.028) were risk factors, while AT-III was a protective factor (OR=0.958; P=0.012) for ACS. Correlation analysis indicated a positive association of Lp-PLA2 level with Gensini scores (r=0.52; P<0.01) and GRACE score (r=0.48; P<0.01), and a negative association between AT-III level and Gensini scores (r=-0.25; P<0.01) and GRACE scores (r=-0.34; P<0.01). The levels of Lp-PLA2 and AT-III exhibited predictive values in patients with ACS, and are associated with the severity of coronary artery stenosis.

View Figures

View References

1	Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 380:2095–2128. 2012. View Article : Google Scholar : PubMed/NCBI
2	Libby P: Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 368:2004–2013. 2013. View Article : Google Scholar : PubMed/NCBI
3	Libby P, Ridker PM and Hansson GK; Leducq Transatlantic Network on Atherothrombosis, . Inflammation in atherosclerosis: From pathophysiology to practice. J Am Coll Cardiol. 54:2129–2138. 2009. View Article : Google Scholar : PubMed/NCBI
4	Dong L, Qu X, Hu ZG, Peng X, Wang Y, Miao Q and Zhang X: Lipoprotein-associated phospholipase A2 is associated with angiographic coronary artery disease and coronary artery risk factors in the elderly. Int J Gerontol. 9:82–86. 2015. View Article : Google Scholar
5	Ikonomidis I, Kadoglou NN, Tritakis V, Paraskevaidis I, Dimas K, Trivilou P, Papadakis I, Tzortzis S, Triantafyllidi H, Parissis J, et al: Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease. Atherosclerosis. 234:34–41. 2014. View Article : Google Scholar : PubMed/NCBI
6	Gilstrap LG and Wang TJ: Biomarkers and cardiovascular risk assessment for primary prevention: An update. Clin Chem. 58:72–82. 2012. View Article : Google Scholar : PubMed/NCBI
7	Cai A, Zheng D, Qiu R, Mai W and Zhou Y: Lipoprotein-associated phospholipase A2 (Lp-PLA(2)): A novel and promising biomarker for cardiovascular risks assessment. Dis Markers. 34:323–331. 2013. View Article : Google Scholar : PubMed/NCBI
8	Cai A, Li G, Chen J, Li X, Li L and Zhou Y: Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population. BMC Cardiovasc Disord. 15:142015. View Article : Google Scholar : PubMed/NCBI
9	Rosenberg RD and Aird WC: Vascular-bed - specific hemostasis and hypercoagulable states. N Engl J Med. 340:1555–1564. 1999. View Article : Google Scholar : PubMed/NCBI
10	Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, Goodman SG, Granger CB, Steg PG, Gore JM, et al; GRACE Investigators, . A validated prediction model for all forms of acute coronary syndrome: Estimating the risk of 6-month postdischarge death in an international registry. JAMA. 291:2727–2733. 2004. View Article : Google Scholar : PubMed/NCBI
11	Gensini GG: A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 51:606. 1983. View Article : Google Scholar : PubMed/NCBI
12	Yang L, Liu Y, Wang S, Liu T and Cong H: Association between Lp-PLA2 and coronary heart disease in Chinese patients. J Int Med Res. 45:159–169. 2017. View Article : Google Scholar : PubMed/NCBI
13	Burke JE, Dennis EA and Phospholipase A: Phospholipase A2 biochemistry. Cardiovasc Drugs Ther. 23:49–59. 2009. View Article : Google Scholar : PubMed/NCBI
14	Ran L, Hao HJ, Liu LL, Luo JJ, Wen JX and Gao F: Biomarkers of atherosclerotic plaque vulnerability and their clinical significance. Chin J Contemp Neurol Neurosurg. 16:566–572. 2016.
15	Maiolino G, Bisogni V, Rossitto G and Rossi GP: Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications. World J Cardiol. 7:609–620. 2015. View Article : Google Scholar : PubMed/NCBI
16	Six DA and Dennis EA: The expanding superfamily of phospholipase A(2) enzymes: Classification and characterization. Biochim Biophys Acta. 1488:1–19. 2000. View Article : Google Scholar : PubMed/NCBI
17	Mattina A, Rosenbaum D, Bittar R, Bonnefont-Rousselot D, Noto D, Averna M, Bruckert E and Giral P: Lipoprotein-associated phospholipase A2 activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia. Nutr Metab Cardiovasc Dis. 28:517–523. 2018. View Article : Google Scholar : PubMed/NCBI
18	Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO and Lerman A: Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: Association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation. 115:2715–2721. 2007. View Article : Google Scholar : PubMed/NCBI
19	Tan HY, Wang N, Li S, Hong M, Wang X and Feng Y: The reactive oxygen species in macrophage polarization: Reflecting its dual role in progression and treatment of human diseases. Oxid Med Cell Longev. 2016:27950902016. View Article : Google Scholar : PubMed/NCBI
20	Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD and Seibel JA; AACE task force for management of dyslipidemia and prevention of atherosclerosis, . American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: Executive summary. Endocr Pract. 18:269–293. 2012. View Article : Google Scholar : PubMed/NCBI
21	Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, Albus C, Benlian P, Boysen G, Cifkova R, et al; European Association for Cardiovascular Prevention & Rehabilitation (EACPR), . European guidelines on cardiovascular disease prevention in clinical practice (version 2012): The fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med. 19:403–488. 2012. View Article : Google Scholar : PubMed/NCBI
22	Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, et al; West of Scotland Coronary Prevention Study Group, . Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 343:1148–1155. 2000. View Article : Google Scholar : PubMed/NCBI
23	Willeit J, Kiechl S, Oberhollenzer F, Rungger G, Egger G, Bonora E, Mitterer M and Muggeo M: Distinct risk profiles of early and advanced atherosclerosis: Prospective results from the Bruneck Study. Arterioscler Thromb Vasc Biol. 20:529–537. 2000. View Article : Google Scholar : PubMed/NCBI
24	Szadujkis-Szadurska K, Grzesk G, Szadujkis-Szadurski L, Gajdus M and Matusiak G: Role of nitric oxide and cGMP in the modulation of vascular contraction induced by angiotensin II and Bay K8644 during ischemia/reperfusion. Exp Ther Med. 5:616–620. 2013. View Article : Google Scholar : PubMed/NCBI
25	Catena C, Colussi G, Brosolo G and Sechi LA: A prothrombotic state is associated with early arterial damage in hypertensive patients. J Atheroscler Thromb. 19:471–478. 2012. View Article : Google Scholar : PubMed/NCBI
26	Koch M and Zernecke A: The hemostatic system as a regulator of inflammation in atherosclerosis. IUBMB Life. 66:735–744. 2014. View Article : Google Scholar : PubMed/NCBI
27	Kubica J, Kozinski M, Krzewina-Kowalska A, Zbikowska-Gotz M, Dymek G, Sukiennik A, Piasecki R, Bogdan M, Grzesk G, Chojnicki M, et al: Combined periprocedural evaluation of CRP and TNF-alpha enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions. Int J Mol Med. 16:173–180. 2005.PubMed/NCBI
28	Thompson SG, Fechtrup C, Squire E, Heyse U, Breithardt G, van de Loo JC and Kienast J: Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris. Arterioscler Thromb Vasc Biol. 16:357–362. 1996. View Article : Google Scholar : PubMed/NCBI
29	Innerfield I, Goldfischer JD, Reicher-Reiss H and Greenberg J: Serum antithrombin in coronary-artery disease. Am J Clin Pathol. 65:64–68. 1976. View Article : Google Scholar : PubMed/NCBI
30	Hong X, Shan PR, Hu L, Huang ZQ, Wu GJ, Xiao FY and Huang WJ: Relationship between antithrombin-III value with acute coronary syndrome and preprocedural TIMI flow grade. Zhonghua Yi Xue Za Zhi. 92:831–834. 2012.(In Chinese). PubMed/NCBI
31	Pedersen OD, Gram J and Jespersen J: Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease. Thromb Haemost. 73:835–840. 1995. View Article : Google Scholar : PubMed/NCBI
32	Brummel-Ziedins K, Undas A, Orfeo T, Gissel M, Butenas S, Zmudka K and Mann KG: Thrombin generation in acute coronary syndrome and stable coronary artery disease: Dependence on plasma factor composition. J Thromb Haemost. 6:104–110. 2008. View Article : Google Scholar : PubMed/NCBI
33	Lipets EN and Ataullakhanov FI: Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk. Thromb J. 13:42015. View Article : Google Scholar : PubMed/NCBI
34	Johnson DJD, Li W, Adams TE and Huntington JA: Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation. EMBO J. 25:2029–2037. 2006. View Article : Google Scholar : PubMed/NCBI
35	Pastorova VE, Bazazian GG and Liapina LA: Antithrombin III activity in long-developing hypercoagulation in animals. Biull Eksp Biol Med. 98:560–563. 1984.(In Russian). View Article : Google Scholar : PubMed/NCBI
36	Schafer AI: The hypercoagulable states. Ann Intern Med. 102:814–828. 1985. View Article : Google Scholar : PubMed/NCBI
37	Winter JH, Bennett B, McTaggart F and Douglas AS: Lipoprotein fractions and antithrombin III consumption during clotting. Thromb Haemost. 47:236–238. 1982. View Article : Google Scholar : PubMed/NCBI